Frankfurt - Delayed Quote EUR

Aspen Pharmacare Holdings Limited (LDZU.F)

Compare
8.65
+0.05
+(0.58%)
At close: January 22 at 8:07:12 AM GMT+1
Currency in ZAR All numbers in thousands
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
44,706,000.00
44,706,000.00
40,709,000.00
38,606,000.00
37,766,000.00
Cost of Revenue
25,252,000.00
25,252,000.00
22,301,000.00
20,300,000.00
19,977,000.00
Gross Profit
19,454,000.00
19,454,000.00
18,408,000.00
18,306,000.00
17,789,000.00
Operating Expense
10,551,000.00
10,551,000.00
9,465,000.00
9,515,000.00
9,664,000.00
Operating Income
8,903,000.00
8,903,000.00
8,943,000.00
8,791,000.00
8,125,000.00
Net Non Operating Interest Income Expense
-1,228,000.00
-1,228,000.00
-815,000.00
-673,000.00
-1,097,000.00
Pretax Income
5,714,000.00
5,714,000.00
6,555,000.00
8,134,000.00
5,989,000.00
Tax Provision
1,310,000.00
1,310,000.00
1,327,000.00
1,646,000.00
1,191,000.00
Net Income Common Stockholders
4,404,000.00
4,404,000.00
5,228,000.00
6,488,000.00
4,806,000.00
Diluted NI Available to Com Stockholders
4,404,000.00
4,404,000.00
5,228,000.00
6,488,000.00
4,806,000.00
Basic EPS
9.91
--
11.77
14.32
10.53
Diluted EPS
9.91
--
11.77
14.32
10.53
Basic Average Shares
444,200.00
--
444,200.00
453,000.00
456,500.00
Diluted Average Shares
444,200.00
--
444,200.00
453,000.00
456,500.00
Total Operating Income as Reported
6,998,000.00
6,998,000.00
7,822,000.00
8,671,000.00
7,072,000.00
Rent Expense Supplemental
--
--
--
50,000.00
84,000.00
Total Expenses
35,803,000.00
35,803,000.00
31,766,000.00
29,815,000.00
29,641,000.00
Net Income from Continuing & Discontinued Operation
4,404,000.00
4,404,000.00
5,228,000.00
6,488,000.00
4,806,000.00
Normalized Income
5,884,320.00
5,884,320.00
5,950,190.00
6,524,708.00
5,600,602.00
Interest Income
1,051,000.00
1,051,000.00
509,000.00
92,000.00
108,000.00
Interest Expense
2,227,000.00
2,227,000.00
1,324,000.00
765,000.00
1,205,000.00
Net Interest Income
-1,228,000.00
-1,228,000.00
-815,000.00
-673,000.00
-1,097,000.00
EBIT
7,941,000.00
7,941,000.00
7,879,000.00
8,899,000.00
7,194,000.00
EBITDA
9,914,000.00
9,914,000.00
9,667,000.00
10,612,000.00
8,847,000.00
Reconciled Cost of Revenue
25,252,000.00
25,252,000.00
22,301,000.00
20,300,000.00
19,977,000.00
Reconciled Depreciation
1,973,000.00
1,973,000.00
1,788,000.00
1,713,000.00
1,653,000.00
Net Income from Continuing Operation Net Minority Interest
4,404,000.00
4,404,000.00
5,228,000.00
6,488,000.00
4,798,000.00
Total Unusual Items Excluding Goodwill
-1,920,000.00
-1,920,000.00
-905,000.00
-46,000.00
-1,002,000.00
Total Unusual Items
-1,920,000.00
-1,920,000.00
-905,000.00
-46,000.00
-1,002,000.00
Normalized EBITDA
11,834,000.00
11,834,000.00
10,572,000.00
10,658,000.00
9,849,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-439,680.00
-439,680.00
-182,810.00
-9,292.00
-199,398.00
6/30/2021 - 12/30/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade